Document Detail

Methotrexate treatment of ectopic pregnancy.
MedLine Citation:
PMID:  7817722     Owner:  NLM     Status:  MEDLINE    
The last decade has witnessed an increasing number of reports indicating that ectopic pregnancy (EP) can be successfully and safely treated with methotrexate (MTX). This review summarizes the results. In large series, as many as 45% of a population of women with EP has been treated with MTX. Success rates of 82-95% have been achieved. Tubal patency on the affected side was preserved in 79-91% of the cases. Preliminary assessment of subsequent fertility suggests that 47-69% will obtain an intrauterine pregnancy. Complications have been only few and of minor importance. However, the majority of reports do not include controls. Randomized studies are needed to optimize patient selection, treatment regimens, long-term toxicity, future fertility, and cost-benefits.
C Floridon; S G Thomsen
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica     Volume:  73     ISSN:  0001-6349     ISO Abbreviation:  Acta Obstet Gynecol Scand     Publication Date:  1994 Nov 
Date Detail:
Created Date:  1995-02-08     Completed Date:  1995-02-08     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0370343     Medline TA:  Acta Obstet Gynecol Scand     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  746-52     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Odense University Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cost-Benefit Analysis
Dose-Response Relationship, Drug
Fertility / drug effects
Methotrexate / therapeutic use*,  toxicity
Pregnancy, Ectopic / drug therapy*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Superficial branch of the radial nerve emerging between two slips of a split brachioradialis muscle ...
Next Document:  Urinary trypsin inhibitor may have a protective effect on endothelial cells in preeclampsia.